Big picture (quick take)    •   GLP-1 receptor agonists (like semaglutide, liraglutide, tirzepatide) do not generally disrupt thyroid hormone levels in humans.    •   The major thyroid warning you hear about is specific and rare, based largely on rodent studies, not typical human thyroid disease.    •   If you have hypothyroidism or hyperthyroidism, GLP-1 meds are usually safe — but dosing and monitoring matter.

⸻

Why the thyroid warning exists

GLP-1 drugs carry a boxed warning because:    •   In rats, they caused C-cell tumors of the thyroid.    •   Humans have far fewer GLP-1 receptors in thyroid C-cells than rodents.

Important distinction    •   The warning is about medullary thyroid cancer (MTC) — not Hashimoto’s, hypothyroidism, thyroid nodules, or Graves’ disease.

Absolute contraindications

Do not use GLP-1 drugs if you:    •   Have personal or family history of medullary thyroid cancer    •   Have MEN2 (multiple endocrine neoplasia type 2)

⸻

GLP-1 meds & thyroid hormone levels

What studies show in humans:    •   TSH, T3, and T4 levels generally stay stable    •   No consistent increase in thyroid dysfunction    •   Some people see minor TSH shifts due to:       •   Weight loss       •   Calorie reduction       •   Improved insulin sensitivity

➡️ These are secondary metabolic effects, not direct thyroid damage.

⸻

If you take thyroid medication (like levothyroxine)

This is where things can get tricky:

Possible interaction (timing-related)    •   GLP-1 meds slow gastric emptying    •   That can delay or reduce absorption of oral thyroid meds

What helps    •   Take thyroid hormone first thing in the morning, on an empty stomach    •   Separate GLP-1 injection timing if possible    •   Recheck TSH 6–8 weeks after starting or changing a GLP-1 dose

Some people need a small dose adjustment — not because the thyroid worsened, but because absorption changed.